Pivotal Parkinson's Disease Clinical Tria... - Cure Parkinson's

Cure Parkinson's

25,343 members26,643 posts

Pivotal Parkinson's Disease Clinical Trial Results Released at the International Movement Disorders Society Congress

Farooqji profile image
1 Reply

The 6-month study involved 92 highly heterogenous subjects who were treated for one hour in the evening. Subjects were assessed during the ON state. A clinically meaningful improvement was found in favor of the Active group over controls on disease severity as measured by the Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (-8.0 LSM difference, p=0.07). Significance was found for the PDQ-39 (-5.7 LSM difference, p<0.05) and non-motor (MDS-UPDRS Part I = -2.5 LSM difference, p<0.01), with a trend on the ESS (-1.5 LSM difference, p=0.05).

wsiltv.com/story/39235146/p...

photopharmics.com/clinical-...

Written by
Farooqji profile image
Farooqji
To view profiles and participate in discussions please or .
Read more about...
1 Reply
KERRINGTON profile image
KERRINGTON

Worth following, and very interesting. I especially like that Mass General, in Boston are involved. They have a great reputation.

You may also like...

The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy Study

patients underwent autonomic (COMPASS-31), motor (MDS-UPDRS and H&Y) and nonmotor (NMSS)...

The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy Study

motor (MDS-UPDRS and H&Y) and nonmotor (NMSS) questionnaires and skin biopsies to evaluate clinical...

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit 2017

slight adverse trends relative to placebo. Adjusted mean changes (worsening) in total UPDRS scores...

Is Parkinson's Disease an Autoimmune Disorder?

Is Parkinson's Disease an Autoimmune Disorder? https://journals.lww.com/neurotodayonline/Fulltext/20

Encouraging results from the CureParkinsons supported Phase II clinical trial of the GLP-1R agonist Liraglutide

the placebo group; MDS-UPDRS III (change from baseline) = not significantly different Secondary...